Cardiol Therapeutics Inc. (TSX:CRDL), a biotechnology company developing proprietary formulations that will treat life-threatening diseases, was featured on BNN Bloomberg’s Market Call with Robert McWhirter. Cardiol uses CBD in its drug formulations due to CBDs anti-inflammatory properties, which could help reduce inflammation in human hearts. The company has teamed up with the University of Alberta to develop an encapsulation process that utilizes nanotechnology to enhance the compatibility of the drugs with the aqueous blood circulation, improve pharmacokinetics and increase drug concentration at the site of disease.

Cardiol also has a partnership with Noramco, a global leader in the manufacturing and supply of controlled drug substance APIs. Under its long-term, exclusive supply agreement, Cardiol will be able to manufacture and supply pure pharmaceutical CBD for Canada and Mexico. According to McWhirter, Cardiol believes that they will be able to produce one million grams of synthetic CBD within 2019, which will allow them to bypass provincial suppliers and licensed producers who are struggling to supply the Canadian cannabis market.

If Cardiol can produce one million grams of CBD and also negotiate supply agreements with Shoppers Drug Mart, for instance, McWhirter believes that the company will be able to meet their quota and start selling their drug formulation. He also thinks that Cardiol will be looking at establishing a US partner to capitalize on the hemp and CBD market there and meet the demand for cannabis-based therapies in both Canada and Mexico.

To view the full video, click here.

Click here to connect with Cardiol Therapeutics Inc. (TSX:CRDL) for an Investor Presentation. 

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less